Dernières nouvelles pour ADC Therapeutics (NYSE:ADCT) Stock

ADC Therapeutics

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.

ADC Therapeutics SA

Trading Ideas

KODK

Eastman Kodak Shares Resume Trade

Piper Sandler analyst Jessica Tassan maintains CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) with a Overweight and lowers the price target from $72 to $64.

News

Price Target

Analyst Ratings

Piper Sandler Maintains Overweight on CVS Health, Lowers Price Target to $64

Barclays analyst Raimo Lenschow maintains Elastic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) with a Overweight and raises the price target from $105 to $138.

ESTC

Barclays Maintains Overweight on Elastic, Raises Price Target to $138

<ul>
<li>75% (12/16) complete response rate observed in relapsed/refractory AL Amyloidosis patients with median 4 prior lines of therapy &nbsp;</li>
<li>Data will be presented on Monday, December 9, 2024 at 4:00 PM PT</li>
</ul>
LOS ANGELES, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and select immune-mediated diseases, today announced that additional NEXICART-1 NXC-201 clinical data in relapsed/refractory AL Amyloidosis has been selected for oral presentation at the upcoming 66th American Society of Hematology (ASH) Annual Meeting to be held in San Diego, California, December 7-10, 2024.

Biotech

General

IMMX

Immix Biopharma Presents NXC-201 Clinical Data In 16 Relapsed/Refractory AL Amyloidosis Patients At 66th American Society of Hematology (ASH) Annual Meeting; 75% (12/16) Complete Response Rate Observed In Relapsed/Refractory AL Amyloidosis Patients With Median 4 Prior Lines Of Therapy

U.S. Supreme Court Declines To Decide Whether Certain Federally Mandated Health Warnings On Cigarette Packs Violate Tobacco Companies' Free Speech Protections

Piper Sandler analyst Mark Lear maintains LandBridge (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LB#NYSE">LB</a>) with a Neutral and raises the price target from $39 to $79.

Piper Sandler Maintains Neutral on LandBridge, Raises Price Target to $79

Barclays analyst Ramsey El-Assal maintains Affirm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) with a Overweight and raises the price target from $64 to $75.

AFRM

Barclays Maintains Overweight on Affirm Holdings, Raises Price Target to $75

Piper Sandler analyst Quinton Gabrielli initiates coverage on SPS Commerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPSC#NASDAQ">SPSC</a>) with a Neutral rating and announces Price Target of $198.

Initiation

SPSC

Piper Sandler Initiates Coverage On SPS Commerce with Neutral Rating, Announces Price Target of $198

Western Digital's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NYSE">WDC</a>) short percent of float has fallen 9.85% since its last report. The company recently reported that it has 16.25 million shares sold short, which is 5.31% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.55 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Western Digital Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732545022_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Western Digital has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Western Digital's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Western Digital's peer group average for short interest as a percentage of float is 6.86%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Western Digital's Recent Short Interest

Mike Tyson's cannabis brand TYSON 2.0 will debut in Jamaica, the brand's holding company, Carma HoldCo Inc, confirmed Friday. In partnership with NUGL Inc's (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NUGL#OTC">NUGL</a>) Kaya Group, TYSON 2.0 will bring its popular line of infused pre-rolls, vapes, pre-packaged flower and concentrates to Jamaican consumers.
Kaya is one of Jamaica's leading medical marijuana companies. Kaya&#8217;s diverse operations include a licensed cultivation facility, processing facility, 3 retail herb houses and one ganja franchise in Punta Del Este, Uruguay. Kaya was the first medicinal Ganja Herb House in the Caribbean. This partnership marks TYSON 2.0&#8217;s entrance into the Caribbean.
Initially, TYSON products will be available at Kaya Herb House locations in St. Ann, Falmouth and in Kingston, with plans to expand into additional retail outlets across Jamaica.
"Bringing TYSON 2.0 to Jamaica is about more than expansion; it&#8217;s about honoring the island's deep-rooted relationship with cannabis," stated Mike Tyson, co-founder and chief brand officer of TYSON 2.0. "Jamaican consumers can now experience the same high quality and dedication we put into every TYSON 2.0 product. I'm excited to share this journey with them."
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/41685387/mike-tysons-marijuana-brand-tyson-2-0-expands-to-arizona-via-partnership-with-desert-fairways">Mike Tyson&#8217;s Marijuana Brand TYSON 2.0 Expands To Arizona Via Partnership With Desert Fairways</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
Adam Wilks, CEO of Carma HoldCo, added, "Expanding into Jamaica is another big win for TYSON 2.0 and Carma HoldCo. Like Amsterdam, Jamaica is a global leader in cannabis culture, making it the perfect destination for our next chapter. Partnering with Kaya Group allows us to merge our premium product lineup with a rich heritage, providing discerning consumers with an unmatched cannabis experience."
Bali Vaswani, CEO of Kaya Group and NUGL, remarked on the partnership's significance: "Our collaboration with TYSON is another defining moment for Jamaica&#8217;s ganja industry. By combining our local expertise in cultivation, processing and our commitment to quality with TYSON 2.0's global reach, we're creating one-of-a-kind ganja experiences. Every herb has a story, and together we're bringing those stories to life, connecting our community to the world."
Since its debut in 2021, TYSON 2.0 expanded beyond the U.S. and into 16 countries and broadened its portfolio to include other premium product categories, cementing its reputation for crafting memorable experiences.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/07/39612472/mike-tyson-to-open-first-branded-retail-store-in-amsterdam-a-city-that-always-held-a-special-pla">Mike Tyson To Open First Branded Retail Store In Amsterdam, A City That Always Held A Special Place In His Heart</a></li>
<li><a href="https://www.benzinga.com/markets/cannabis/24/11/41693389/exclusive-mike-tyson-and-st-ndenglass-unveil-the-tyson-2-0-mod-l-dok-travel-set">EXCLUSIVE: Mike Tyson And Stündenglass Unveil The TYSON 2.0 Modül + Dok Travel Set</a></li>
</ul>
Courtesy Photo

Cannabis

NUGL

Mike Tyson's Cannabis Infused Pre-Rolls And Vapes Reach Jamaica Via Kaya Group Partnership

Modine Manufacturing's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOD#NYSE">MOD</a>) short percent of float has fallen 7.21% since its last report. The company recently reported that it has 3.43 million shares sold short, which is 7.46% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.68 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Modine Manufacturing Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732545016_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Modine Manufacturing has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Modine Manufacturing's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Modine Manufacturing's peer group average for short interest as a percentage of float is 6.81%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Modine Manufacturing's Recent Short Interest

First Solar's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NYSE">FSLR</a>) short percent of float has risen 20.26% since its last report. The company recently reported that it has 6.01 million shares sold short, which is 7.36% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.91 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>First Solar Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732545011_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for First Solar has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing First Solar's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, First Solar's peer group average for short interest as a percentage of float is 4.60%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

FSLR

(FSLR) - Analyzing First Solar's Short Interest

Piper Sandler analyst Quinton Gabrielli initiates coverage on Manhattan Associates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>) with a Overweight rating and announces Price Target of $326.

MANH

Piper Sandler Initiates Coverage On Manhattan Associates with Overweight Rating, Announces Price Target of $326

Benchmark analyst Mark Palmer maintains MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) with a Buy and raises the price target from $450 to $650.

MSTR

Benchmark Maintains Buy on MicroStrategy, Raises Price Target to $650

Barclays analyst Saket Kalia maintains Ncino (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNO#NASDAQ">NCNO</a>) with a Equal-Weight and raises the price target from $34 to $44.

NCNO

Barclays Maintains Equal-Weight on Ncino, Raises Price Target to $44

On Monday, Cassava Sciences Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>) stock plunged after the company released topline data from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42160859/cassava-sciences-topline-phase-3-data-did-not-meet-co-primary-endpoints" rel="noreferrer noopener">Alzheimer&#8217;s disease</a>.
The trial did not meet the pre-specified co-primary, secondary, and exploratory biomarker endpoints.
In July, CEO Rick Barry wrote a letter to shareholders and employees, saying that the company is in the final stages of testing simufilam and has significant&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41065699/sec-charges-cassava-sciences-over-manipulated-alzheimers-trial-data-company-and-former-execs-agre" rel="noreferrer noopener">financial and emotional stakes</a>.
The co-primary endpoints were the change in cognition and function from baseline to the end of the double-blind treatment period at week 52, assessed by the ADAS-COG12 and ADCS-ADL scales, comparing simufilam to placebo.
Simufilam continued to demonstrate an overall favorable safety profile.
&#8220;The results are disappointing&#8230;We took careful measures to enroll patients with mild-to-moderate AD. Despite that, the loss of cognition in the placebo group was less pronounced than was previously reported in other placebo-controlled studies in AD&#8230;&#8221; said&nbsp;Rick Barry, President and Chief Executive Officer.
The company said the failed trial results have impacted its second Phase 3 trial,&nbsp;ReFocus-ALZ, and decided to discontinue ReFocus-ALZ. The company will also be discontinuing the Open Label Extension study.
The complete 52-week dataset will be available from the study along with a large portion of 76-week data.
Cassava will continue to review the data and evaluate the next steps. We plan to share the detailed results at a future medical meeting.
Cassava has been in the headlines for fabricating data from <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41231890/whats-going-on-with-alzheimers-focused-cassava-sciences-on-tuesday" rel="noreferrer noopener">simufilam drug trials</a>.
In September, Cassava Sciences&nbsp;agreed to pay over $40 million to resolve SEC charges over misleading statements related to a Phase 2 trial of the company&#8217;s controversial&nbsp;Alzheimer&#8217;s drug, simufilam.
The SEC also&nbsp;charged&nbsp;Hoau-Yan Wang, a consultant and co-developer of the drug, with manipulating trial results.
The SEC&#8217;s investigation found that in&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/21/08/22653801/cassava-sciences-shares-sink-with-alzheimers-drug-mired-in-controversy" rel="noreferrer noopener">September 2020</a>, Cassava disclosed manipulated data from the trial, which falsely suggested dramatic improvements in Alzheimer&#8217;s biomarkers like total tau and phosphorylated tau.
Price Action: SAVA stock is down 84.2% at $4.19 during the premarket session at last check Monday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42163927/fda-approves-bridgebio-pharmas-drug-for-rare-heart-disease-poised-to-challenge-pfizer-in-lucrative-yet-competitive-market" target="_blank" rel="noreferrer noopener">FDA Approves BridgeBio Pharma&#8217;s Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market</a></li>
</ul>

Equities

Health Care

Movers

SAVA

Cassava Sciences' Controversial Alzheimer's Drug Fails To Hit Primary Goal In Pivotal Study, Halts Late-Stage Studies

Barclays analyst Alexia Dogani maintains ZIM Integrated Shipping (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) with a Underweight and raises the price target from $13.9 to $16.5.

Barclays Maintains Underweight on ZIM Integrated Shipping, Raises Price Target to $16.5

Semler Scientific Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) shares are trading higher Monday. The company launched an offering and provided an update on its Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) <a href="https://www.benzinga.com/pressreleases/24/11/n42160050/semler-scientific-announces-updated-btc-and-atm-activity">holdings</a>.
What Happened: Semler Scientific announced that it acquired 297 Bitcoin for $29.1 million in cash between Nov. 18 and Nov. 22. The company made the purchases at an average price of $97,995 per Bitcoin. 
As of Friday, Semler held a total of 1,570 Bitcoin, acquired for an aggregate of $117.8 million. 
Semler Scientific entered into a Controlled Equity Offering&nbsp;Sales Agreement with Cantor Fitzgerald in August, under which Semler may offer and sell its common stock in an at-the-market offering from time to time.
The company filed a prospectus supplement on Monday to offer an additional $50 million of shares under its existing offering with Cantor, bringing the total offering amount up to $100 million. 
Several crypto-related stocks have rallied in recent weeks as Bitcoin prices have climbed to new all-time highs just below the $100,000 level. Bitcoin was up 0.24% over a 24-hour period, trading at $97,700 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. 
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42155055/crypto-analyst-bitcoin-poised-to-skyrocket-to-180k-and-eventually-top-1m#google_vignette">Crypto Analyst: Bitcoin Poised To Skyrocket To $180K and &#8216;Eventually&#8217; Top $1M</a>
SMLR Price Action: Semler Scientific shares were up 5.11% at $66.90 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Offerings

$BTC

SMLR

What's Going On With Semler Scientific Stock Monday?

JP Morgan analyst Michael Rehaut maintains AZEK Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZEK#NYSE">AZEK</a>) with a Overweight and raises the price target from $48 to $58.

AZEK

JP Morgan Maintains Overweight on AZEK Co, Raises Price Target to $58

Morgan Stanley analyst Erik Woodring reiterates Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) with a Overweight and maintains $273 price target.

Reiteration

AAPL

Morgan Stanley Reiterates Overweight on Apple, Maintains $273 Price Target

ADC Therapeutics SA 2024 Q2 - Results - Earnings Call Presentation

Week In Review: UCB Sells China Drug Portfolio For $680 Million To CBC

ADC Therapeutics Ltd (ADCT) has disclosed a new risk, in the Innovation / R&D category. ADC Therapeutics Ltd faces considerable uncertainty with it...

ADC Therapeutics and the Perils of Outsourced Trials: Navigating the Uncertainty of ZYNLONTA's Phase 2 Study

ADC Therapeutics Non-GAAP EPS of -$0.28, revenue of $18.46M misses by $0.04M

Reports Q3 revenue $18M, consensus $18.46M. "We are excited about the advancements in our ZYNLONTA(R) trials in earlier lines of diffuse large B-ce...

ADC Therapeutics reports Q3 adjusted EPS (28c), consensus (39c)

Stephens initiated coverage of ADC Therapeutics (ADCT) with an Overweight rating and $6 price target Published first on TheFly – the ultimate sourc...

ADC Therapeutics initiated with an Overweight at Stephens

Stephens initiated coverage of ADC Therapeutics (ADCT) with an Overweight rating and $6 price target as the firm is adding to its biotechnology res...

ADC Therapeutics initiated with an Overweight at Stephens on Zynlonta potential

ADC Therapeutics Ltd ( ($ADCT) ) has released its Q3 earnings. Here is a breakdown of the information ADC Therapeutics Ltd presented to its investo...

ADC Therapeutics Highlights Q3 Advances and Strategic Focus

RBC Capital analyst Gregory Renza maintained a Buy rating on ADC Therapeutics (ADCT – Research Report) yesterday and set a price target of $8.00. T...

Comments

ADC Therapeutics

Actualités

Dernières nouvelles pour ADC Therapeutics (NYSE:ADCT) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL